HEPA Archives - Page 11 of 11

Executive Moves

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharmaceuticals (NASDAQ:HEPA) promoted Daren Ure, Daniel Trepanier and Patrick Mayo to the new roles of CSO; SVP of drug development; and SVP of clinical pharmacology, respectively, to further advance the...

October 3, 2019

Developments

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...

August 14, 2019

Executive Moves

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Stephen Harrison Dr. Stephen Harrison, a leading authority on liver diseases, has joined the scientific advisory board (SAB) of Hepion Pharmaceuticals (NASDAQ:HEPA). Dr. Harrison is a visiting professor of hepatology at...

August 7, 2019

Developments

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Hepion Pharmaceuticals (NASDAQ:HEPA) has partnered with Applied Pharmaceutical Innovation (API) to expand its research capabilities and further characterize its lead candidate, CRV431. API is an independent institute...

July 31, 2019

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Developments

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

The FDA has authorized Hepion Pharmaceuticals (NASDAQ:HEPA) to proceed with its IND opening study of CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “Based on the preclinical and clinical studies we’ve...

July 29, 2019

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Developments

ContraVir Pharma to present CRV431 Phase 1 data at Intl Liver Congress

ContraVir Pharmaceuticals (NASDAQ:CTRV) will present a poster on a Phase 1 single ascending dose study of its drug candidate, CRV431, at the International Liver Congress, taking place in Vienna, Austria from April 10-to...

April 11, 2019

Executive Moves

ContraVir Pharma names biotech industry veteran, Robert Foster, as acting CEO

ContraVir Pharmaceuticals (NASDAQ:CTRV) appointed industry veteran, Robert Foster, as acting CEO, succeeding James Sapirstein.

October 3, 2018

Tag - HEPA

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharma to present CRV431 Phase 1 data at Intl Liver Congress

ContraVir Pharma names biotech industry veteran, Robert Foster, as acting CEO

General

More